Literature DB >> 18649390

Neuronal gene expression correlates of Parkinson's disease with dementia.

Chelsea Stamper1, Andrew Siegel, Winnie S Liang, John V Pearson, Dietrich A Stephan, Holly Shill, Don Connor, John N Caviness, Marwan Sabbagh, Thomas G Beach, Charles H Adler, Travis Dunckley.   

Abstract

Dementia is a common disabling complication in patients with Parkinson's disease (PD). The underlying molecular causes of Parkinson's disease with dementia (PDD) are poorly understood. To identify candidate genes and molecular pathways involved in PDD, we have performed whole genome expression profiling of susceptible cortical neuronal populations. Results show significant differences in expression of 162 genes (P < 0.01) between PD patients who are cognitively normal (PD-CogNL) and controls. In contrast, there were 556 genes (P < 0.01) significantly altered in PDD compared to either healthy controls or to PD-CogNL cases. These results are consistent with increased cortical pathology in PDD relative to PD-CogNL and identify underlying molecular changes associated with the increased pathology of PDD. Lastly, we have identified expression differences in 69 genes in PD cortical neurons that occur before the onset of dementia and that are exacerbated upon the development of dementia, suggesting that they may be relevant presymptomatic contributors to the onset of dementia in PD. These results provide new insights into the cortical molecular changes associated with PDD and provide a highly useful reference database for researchers interested in PDD. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18649390      PMCID: PMC2666445          DOI: 10.1002/mds.22184

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  24 in total

1.  Health related quality of life in Parkinson's disease: a prospective longitudinal study.

Authors:  K H Karlsen; E Tandberg; D Arsland; J P Larsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-11       Impact factor: 10.154

2.  The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.

Authors:  N Ostrerova-Golts; L Petrucelli; J Hardy; J M Lee; M Farer; B Wolozin
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

3.  Parkin and synphilin-1 isoform expression changes in Lewy body diseases.

Authors:  Jordi Humbert; Katrin Beyer; Cristina Carrato; José L Mate; Isidro Ferrer; Aurelio Ariza
Journal:  Neurobiol Dis       Date:  2007-03-27       Impact factor: 5.996

4.  Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease.

Authors:  Enikö Kövari; Gabriel Gold; François R Herrmann; Alessandra Canuto; Patrick R Hof; Constantin Bouras; Panteleimon Giannakopoulos
Journal:  Acta Neuropathol       Date:  2003-04-10       Impact factor: 17.088

5.  A Drosophila model of Parkinson's disease.

Authors:  M B Feany; W W Bender
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

6.  Rapid brain autopsy. The Joseph and Kathleen Bryan Alzheimer's Disease Research Center experience.

Authors:  C M Hulette; K A Welsh-Bohmer; B Crain; M H Szymanski; N O Sinclaire; A D Roses
Journal:  Arch Pathol Lab Med       Date:  1997-06       Impact factor: 5.534

7.  Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.

Authors:  Deniz Kirik; Carl Rosenblad; Corinna Burger; Cecilia Lundberg; Teit E Johansen; Nicholas Muzyczka; Ronald J Mandel; Anders Björklund
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

8.  Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease.

Authors:  P M Mattila; J O Rinne; H Helenius; D W Dickson; M Röyttä
Journal:  Acta Neuropathol       Date:  2000-09       Impact factor: 17.088

9.  Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.

Authors:  Deniz Kirik; Lucy E Annett; Corinna Burger; Nicholas Muzyczka; Ronald J Mandel; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-24       Impact factor: 11.205

Review 10.  What causes mental dysfunction in Parkinson's disease?

Authors:  Murat Emre
Journal:  Mov Disord       Date:  2003-09       Impact factor: 10.338

View more
  20 in total

Review 1.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

Review 2.  The role of FUS gene variants in neurodegenerative diseases.

Authors:  Hao Deng; Kai Gao; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2014-05-20       Impact factor: 42.937

Review 3.  Current status and future directions of gene expression profiling in Parkinson's disease.

Authors:  James G Greene
Journal:  Neurobiol Dis       Date:  2010-11-05       Impact factor: 5.996

4.  Loss of fused in sarcoma (FUS) promotes pathological Tau splicing.

Authors:  Denise Orozco; Sabina Tahirovic; Kristin Rentzsch; Benjamin M Schwenk; Christian Haass; Dieter Edbauer
Journal:  EMBO Rep       Date:  2012-06-19       Impact factor: 8.807

5.  Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases.

Authors:  Paula Desplats; Brian Spencer; Elizabeth Coffee; Pruthul Patel; Sarah Michael; Christina Patrick; Anthony Adame; Edward Rockenstein; Eliezer Masliah
Journal:  J Biol Chem       Date:  2011-02-04       Impact factor: 5.157

6.  Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.

Authors:  Thomas G Beach; Charles H Adler; Lucia I Sue; Geidy Serrano; Holly A Shill; Douglas G Walker; LihFen Lue; Alex E Roher; Brittany N Dugger; Chera Maarouf; Alex C Birdsill; Anthony Intorcia; Megan Saxon-Labelle; Joel Pullen; Alexander Scroggins; Jessica Filon; Sarah Scott; Brittany Hoffman; Angelica Garcia; John N Caviness; Joseph G Hentz; Erika Driver-Dunckley; Sandra A Jacobson; Kathryn J Davis; Christine M Belden; Kathy E Long; Michael Malek-Ahmadi; Jessica J Powell; Lisa D Gale; Lisa R Nicholson; Richard J Caselli; Bryan K Woodruff; Steven Z Rapscak; Geoffrey L Ahern; Jiong Shi; Anna D Burke; Eric M Reiman; Marwan N Sabbagh
Journal:  Neuropathology       Date:  2015-01-26       Impact factor: 1.906

7.  Transcriptomic profiles in Parkinson's disease.

Authors:  Lille Kurvits; Freddy Lättekivi; Ene Reimann; Liis Kadastik-Eerme; Kristjan M Kasterpalu; Sulev Kõks; Pille Taba; Anu Planken
Journal:  Exp Biol Med (Maywood)       Date:  2020-11-04

Review 8.  Phytochemicals as Regulators of Genes Involved in Synucleinopathies.

Authors:  Andrei Surguchov; Libby Bernal; Alexei A Surguchev
Journal:  Biomolecules       Date:  2021-04-22

9.  Oxr1 is essential for protection against oxidative stress-induced neurodegeneration.

Authors:  Peter L Oliver; Mattéa J Finelli; Benjamin Edwards; Emmanuelle Bitoun; Darcy L Butts; Esther B E Becker; Michael T Cheeseman; Ben Davies; Kay E Davies
Journal:  PLoS Genet       Date:  2011-10-20       Impact factor: 5.917

Review 10.  Gene expression profiling in human neurodegenerative disease.

Authors:  Johnathan Cooper-Knock; Janine Kirby; Laura Ferraiuolo; Paul R Heath; Magnus Rattray; Pamela J Shaw
Journal:  Nat Rev Neurol       Date:  2012-08-14       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.